title: [Evaluation of immune reconstitution with in vitro-activated T cells from a tumor-bearing host].
abstract: OBJECTIVE
  To evaluate the reconstituted immune system with in vitro-activated T cells from tumor-bearing rats coupled with ovarian cancer vaccination.
  
  
  METHODS
  Fischer 344 female rats were injected with cyclophosphamide (CY) as a lymphopenia (LP) model. The immune systems of the rats were reconstituted with in vitro-activated T cells from the same individuals. GM-CSF-modified ovarian cancer cells lines (NuTu-19) were injected within 24 h after immune reconstitution. The tumor vaccine draining lymph nodes (TVDLN) were harvested 8-10 days after vaccination and analyzed by FACS. The proliferative capacity of dendritic cells (DCs) was measured by the levels of MHC-II and CD86 molecules. The activation of T cells was monitored by the percentage of FITC-CD4 and PE-CD8 cells. The biological function of DCs such as processing and presenting antigens was assayed by immature DCs' phagocytosis of FITC-Dextran.
  
  
  RESULTS
  Immune reconstitution with in vitro-activated T cells produced significantly more DCs, T cells and functionally enhanced immature DCs out of TVDLN.
  
  
  CONCLUSIONS
  Reconstituting immune system with in vitro-activated T cells from a tumor-bearing host coupled with ovarian cancer vaccination during lymphocytopenia may selectively expand and activate particular T cells and DCs, leading to augmentation of anti-tumor immunity.
authors.affiliation: Department of Obstetrics and Gynecology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Qi-ling
authors.initials: QL
authors.lastname: Li
authors.forename: Cai-xia
authors.initials: CX
authors.lastname: Feng
authors.forename: Shang-feng
authors.initials: SF
authors.lastname: Gao
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
authors.forename: Yun-ping
authors.initials: YP
authors.lastname: Wang
authors.forename: Yue-ling
authors.initials: YL
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000818:Animals; D051940:B7-2 Antigen / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000633:toxicity; D003713:Dendritic Cells / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D005802:Genes, MHC Class II / Q000502:physiology; D008231:Lymphopenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000276:immunology; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D051940:B7-2 Antigen; D019496:Cancer Vaccines; D003520:Cyclophosphamide